文献速递血栓与止血

ABO血型与癌症患者静脉血栓栓塞风险

ABO blood group type and risk of venous thromboembolism in patients with cancer.
PubMed 文献 · Blood Adv · 2022-01-01

非O血型在随访前3个月与VTE风险无关(SHR 1.00),此后与VTE风险升高相关(SHR 1.79),在中低血栓风险肿瘤类型中相关(SHR 1.73),在极高风险类型中无关(SHR 0.94),校正因子VIII后该关联减弱。

要点

  • 非O血型是癌症患者VTE的时间依赖性预测因素。
  • 随访3个月后非O血型与VTE风险升高相关(SHR 1.79)。
  • 中低血栓风险肿瘤类型中非O血型与VTE风险升高相关(SHR 1.73)。

核心结论

  • 非O血型是癌症患者VTE的时间依赖性预测因素,与随访3个月后VTE风险升高及中低风险肿瘤类型患者的VTE风险升高相关。

研究设计与样本

  • 在维也纳癌症与血栓形成研究(一项前瞻性队列研究)中进行分析,纳入新诊断或复发癌症患者,主要结局为VTE。

主要发现

  • 151例患者发生VTE(8.8%)。
  • 随访前3个月内,非O血型与VTE风险无关联(SHR 1.00;95%CI 0.60-1.67)。
  • 此后,非O血型与更高的VTE风险相关(SHR 1.79;95%CI 1.12-2.85)。
  • 非O血型与中低血栓风险肿瘤类型患者的VTE风险升高相关(SHR 1.73;95%CI 1.09-2.73),但在极高风险类型(胰腺癌、胃食管癌和脑癌)中无关(SHR 0.94;95%CI 0.55-1.61)。
  • 校正因子VIII后该关联减弱。

局限性

  • 校正因子VIII后该关联减弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is common in patients with cancer. Although in the general population blood type non-O is associated with increased VTE risk, the impact of ABO blood type on risk of cancer-associated VTE has not been clarified. To determine the influence of ABO blood type on cancer-associated VTE risk, we conducted an analysis within the Vienna Cancer and Thrombosis Study, a prospective cohort study including patients with newly diagnosed or recurrent cancer observed for the primary outcome VTE. Restricted cubic spline analysis was performed and specific time-restricted subdistribution hazard ratios (SHR) were calculated to investigate the association between non-O blood type and VTE over time. One thousand, seven hundred and eight patients were included in the analysis (median follow-up time: 24 months; interquartile range: 10-24), and 151 patients developed VTE (8.8%). During the first 3 months of follow-up, there was no association between non-O blood type and VTE risk (SHR: 1.00; 95% confidence interval [CI]: 0.60-1.67). Thereafter, non-O blood type was associated with a higher VTE risk (SHR: 1.79; 95% CI: 1.12-2.85). Furthermore, non-O blood type was associated with increased VTE risk in patients with intermediate and low thrombotic risk tumor types (SHR: 1.73; 95% CI: 1.09-2.73) but not in very high-risk types (pancreatic, gastroesophageal, and brain cancer; SHR: 0.94; 95% CI: 0.55-1.61). This association was weakened after adjustment for factor VIII. Non-O blood type is a time-dependent predictor of VTE in patients with cancer. It is associated with increased VTE risk beyond 3 months of follow-up and in patients with intermediate- and low-risk tumor types.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Englisch C, Moik F, Nopp S, et al. ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Adv. 2022. PMID: 35416922. doi:10.1182/bloodadvances.2021006283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。